Huadong Medicine Co Ltd - Asset Resilience Ratio

Latest as of June 2024: 0.05%

Huadong Medicine Co Ltd (000963) has an Asset Resilience Ratio of 0.05% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Huadong Medicine Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥16.49 Million
≈ $2.41 Million USD Cash + Short-term Investments

Total Assets

CN¥36.17 Billion
≈ $5.29 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2017)

This chart shows how Huadong Medicine Co Ltd's Asset Resilience Ratio has changed over time. See Huadong Medicine Co Ltd (000963) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Huadong Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Huadong Medicine Co Ltd (000963) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥16.49 Million 0.05%
Total Liquid Assets CN¥16.49 Million 0.05%

Asset Resilience Insights

  • Limited Liquidity: Huadong Medicine Co Ltd maintains only 0.05% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Huadong Medicine Co Ltd Industry Peers by Asset Resilience Ratio

Compare Huadong Medicine Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 1.96%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Guobang Pharma Ltd
SHG:605507
Drug Manufacturers - Specialty & Generic 8.47%

Annual Asset Resilience Ratio for Huadong Medicine Co Ltd (2000–2017)

The table below shows the annual Asset Resilience Ratio data for Huadong Medicine Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2017-12-31 4.25% CN¥680.00 Million
≈ $99.51 Million
CN¥15.99 Billion
≈ $2.34 Billion
+3.22pp
2016-12-31 1.04% CN¥150.00 Million
≈ $21.95 Million
CN¥14.46 Billion
≈ $2.12 Billion
+1.01pp
2014-12-31 0.03% CN¥2.50 Million
≈ $365.83K
CN¥9.01 Billion
≈ $1.32 Billion
-0.79pp
2005-12-31 0.82% CN¥16.86 Million
≈ $2.47 Million
CN¥2.05 Billion
≈ $300.54 Million
-0.13pp
2004-12-31 0.95% CN¥16.86 Million
≈ $2.47 Million
CN¥1.77 Billion
≈ $258.79 Million
+0.91pp
2003-12-31 0.05% CN¥661.00K
≈ $96.73K
CN¥1.43 Billion
≈ $209.98 Million
-9.11pp
2000-12-31 9.16% CN¥104.74 Million
≈ $15.33 Million
CN¥1.14 Billion
≈ $167.32 Million
--
pp = percentage points

About Huadong Medicine Co Ltd

SHE:000963 China Drug Manufacturers - Specialty & Generic
Market Cap
$8.56 Billion
CN¥58.50 Billion CNY
Market Cap Rank
#2504 Global
#316 in China
Share Price
CN¥33.35
Change (1 day)
-0.57%
52-Week Range
CN¥33.35 - CN¥46.17
All Time High
CN¥96.84
About

Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. It operates through Pharmaceutical Industry, Pharmaceutical Business, Aesthetic Medicine, and Industrial Microbiology segments. The company distributes Chinese and western medicines, Chinese herbal medicines, and medical instruments; and immunosup… Read more